Nexalin Technology, Inc. (NXL) Dividend History

Nexalin Technology, Inc. (NXL) is a healthcare company that develops and markets neurostimulation devices aimed at treating neurological and psychiatric conditions, such as anxiety, depression, and chronic pain. The company's non-invasive, transcranial electrical stimulation devices are designed to provide therapeutic relief through electrical impulses delivered to specific areas of the brain.

1776 Yorktown, Houston, TX, 77056
Phone: (832) 260-0222
Website: https://www.nexalin.com

Dividend History

Pay Date	Amount	Ex Dividend Date	Record Date
April 16, 2007	$0.31	03/23/2007	03/27/2007
January 16, 2007	$0.31	01/03/2007	01/05/2007
October 16, 2006	$0.31	09/28/2006	10/02/2006
July 17, 2006	$0.31	06/29/2006	07/03/2006
April 17, 2006	$0.31	03/30/2006	04/03/2006
January 17, 2006	$0.31	12/29/2005	01/03/2006
October 17, 2005	$0.31	09/29/2005	10/03/2005
September 27, 2005	$3.00	08/23/2005	08/25/2005
July 15, 2005	$0.41	06/29/2005	07/01/2005
April 15, 2005	$0.41	03/30/2005	04/01/2005
January 18, 2005	$0.41	12/30/2004	01/03/2005
October 15, 2004	$0.41	09/29/2004	10/01/2004
July 15, 2004	$0.41	06/29/2004	07/01/2004
April 15, 2004	$0.41	03/30/2004	04/01/2004

Dividends Summary

Nexalin Technology, Inc. has issued 14 dividend payments over the past 3 years
The most recent dividend was paid 6627 days ago, on April 16, 2007
The first recorded dividend was paid on April 15, 2004
The highest dividend payout was $3.00 per share
The average dividend over this 3 year span is $0.55 per share
Nexalin Technology, Inc. has decreased its dividend payments by 24.24% since 2004

Company News

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, announced the closing of a $5.0 million public offering of its common stock.

GlobeNewswire Inc.
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has been appointed as the Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment reflects Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders.

GlobeNewswire Inc.
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology, Inc. is hosting a webinar to discuss its non-invasive, frequency-based deep brain stimulation device and progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. The company's solutions have shown clinically meaningful improvements in treating conditions like insomnia, PTSD, and traumatic brain injuries, positioning Nexalin as an emerging leader in a growing market.

GlobeNewswire Inc.
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nexalin Technology, a leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, has launched Phase 1 of its proprietary virtual clinic. The clinic will utilize AI, Electronic Data Capture (EDC), and Patient Monitoring System (PMS) to provide a virtual treatment experience for patients while enabling real-time data acquisition and analysis.

GlobeNewswire Inc.
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

A new peer-reviewed publication validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) technology, highlighting its ability to non-invasively treat challenging psychiatric conditions and its potential to become a cornerstone in mental health treatment.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:06:38 UTC